Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces in Cystic Fibrosis.
作者信息
Morgan Sarah J, Nichols David P, Ni Windy, Hong Gina, Salipante Stephen J, Solomon George M, Rowe Steven M, Clancy John P, Cramer Robert A, Singh Pradeep K
机构信息
Departments of Microbiology and Medicine, University of Washington, Seattle, Washington, USA.
Cystic Fibrosis Foundation, Bethesda, Maryland, USA.
出版信息
Am J Respir Crit Care Med. 2024 Nov 1;210(9):1155-1158. doi: 10.1164/rccm.202406-1128RL.
Abstract
摘要
相似文献
1
Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces in Cystic Fibrosis.依列卡福妥/替扎卡福妥/依伐卡托显著降低囊性纤维化患者的（相关指标，原文未明确具体所指）。
Am J Respir Crit Care Med. 2024 Nov 1;210(9):1155-1158. doi: 10.1164/rccm.202406-1128RL.
2
Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.高效CFTR调节剂疗法对囊性纤维化患儿的实际影响。
Front Pharmacol. 2023 May 9;14:1176815. doi: 10.3389/fphar.2023.1176815. eCollection 2023.
3
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.12岁及以上囊性纤维化患者使用万扎卡托-替扎卡托-地替瓦卡托与依列卡托-替扎卡托-艾伐卡托的对比研究（SKYLINE试验VX20 - 121 - 102和VX20 - 121 - 103）：两项随机、活性对照3期试验的结果
Lancet Respir Med. 2025 Mar;13(3):256-271. doi: 10.1016/S2213-2600(24)00411-9. Epub 2025 Jan 2.
4
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
5
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.依列卡福妥联合替扎卡福妥和依伐卡托对比替扎卡福妥联合依伐卡托治疗F508del-CFTR纯合子囊性纤维化患者的疗效和安全性：一项为期24周的多中心、随机、双盲、活性对照3b期试验
Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20.
6
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
7
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.无 F508del CFTR 变异的囊性纤维化患者使用依伐卡托、泰它西普和埃拉卡托的法国扩大同情用药计划：一项真实世界研究。
Lancet Respir Med. 2024 Nov;12(11):888-900. doi: 10.1016/S2213-2600(24)00208-X. Epub 2024 Aug 13.
8
Efficacy of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis.依伐卡托与泰他卡托和艾克巴司他联合制剂治疗囊性纤维化慢性鼻-鼻窦炎的疗效。
Am J Otolaryngol. 2024 May-Jun;45(3):104236. doi: 10.1016/j.amjoto.2024.104236. Epub 2024 Feb 24.
9
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对具有 II 类 CFTR 基因突变（最常见的是 F508del）的囊性纤维化患者的校正治疗（含或不含增效剂）。
Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3.
10
Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes.囊性纤维化-门控和-残留功能基因型的三联疗法。
N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665.
引用本文的文献
1
Deleterious effect of on F508del-CFTR rescued by elexacaftor/tezacaftor/ivacaftor is clinical strain-dependent in patient-derived nasal cells.依列卡福妥/替扎卡福妥/依伐卡托对F508del-CFTR的挽救作用在患者来源的鼻细胞中存在临床菌株依赖性。
ERJ Open Res. 2025 May 27;11(3). doi: 10.1183/23120541.00970-2024. eCollection 2025 May.
2
Epidemiology, antifungal susceptibility and biological characteristics of clinical Aspergillus fumigatus in a tertiary hospital.某三级医院临床烟曲霉的流行病学、抗真菌药敏性及生物学特性
Sci Rep. 2025 May 15;15(1):16906. doi: 10.1038/s41598-025-00187-z.
3
Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators.高效CFTR调节剂时代囊性纤维化个性化医疗的进展
Mol Cell Pediatr. 2025 May 5;12(1):6. doi: 10.1186/s40348-025-00194-0.
4
The impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the pulmonary microbiota.囊性纤维化跨膜传导调节因子（CFTR）调节剂对肺部微生物群的影响。
Microbiology (Reading). 2025 Apr;171(4). doi: 10.1099/mic.0.001553.
5
Recent developments in research: diversity, drugs, and disease.研究的最新进展：多样性、药物与疾病。
Microbiol Mol Biol Rev. 2025 Mar 27;89(1):e0001123. doi: 10.1128/mmbr.00011-23. Epub 2025 Feb 10.
6
Confronting the Fungus among Us in the Airways of People with Cystic Fibrosis.直面囊性纤维化患者气道中的真菌
Ann Am Thorac Soc. 2025 Feb;22(2):183-184. doi: 10.1513/AnnalsATS.202411-1229ED.
7
Influence of Fungal Colonization on Exacerbations in Patients with Cystic Fibrosis.真菌定植对囊性纤维化患者病情加重的影响。
J Fungi (Basel). 2024 Dec 17;10(12):875. doi: 10.3390/jof10120875.
8
The Real-World Effectiveness of Antifungals in People with Cystic Fibrosis and -Positive Cultures.抗真菌药物在囊性纤维化及培养结果呈阳性患者中的真实世界有效性
Ann Am Thorac Soc. 2025 Feb;22(2):193-199. doi: 10.1513/AnnalsATS.202312-1070OC.
本文引用的文献
1
The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of biofilms.囊性纤维化治疗药物 Trikafta 会影响生物膜的生长、存活和细胞壁。
mBio. 2023 Oct 31;14(5):e0151623. doi: 10.1128/mbio.01516-23. Epub 2023 Oct 13.
2
Infection, Allergy, and Inflammation: The Role of in Cystic Fibrosis.感染、过敏与炎症：[具体物质或因素]在囊性纤维化中的作用 。（原文中“in”后面的内容缺失）
Microorganisms. 2023 Aug 5;11(8):2013. doi: 10.3390/microorganisms11082013.
3
Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.依伐卡托/泰他卡托/艾美卡替三联复方制剂对囊性纤维化患者痰液黏弹性特性、气道感染和炎症的纵向影响。
Eur Respir J. 2023 Aug 3;62(2). doi: 10.1183/13993003.02153-2022. Print 2023 Aug.
4
Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist.药物改善 CFTR 功能可迅速降低痰中病原体密度，但肺部感染通常持续存在。
J Clin Invest. 2023 May 15;133(10):e167957. doi: 10.1172/JCI167957.
5
Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: What consequences on Aspergillus-related diseases? Preliminary insights.用于治疗囊性纤维化的依列卡福/替扎卡福/艾伐卡福的出现：对曲霉相关疾病有何影响？初步见解。
J Cyst Fibros. 2022 Nov;21(6):1084-1085. doi: 10.1016/j.jcf.2022.09.007. Epub 2022 Sep 21.
6
in the cystic fibrosis lung: pros and cons of azole therapy.在囊性纤维化肺部：唑类疗法的利弊
Infect Drug Resist. 2016 Sep 20;9:229-238. doi: 10.2147/IDR.S63621. eCollection 2016.
7
Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center.在一家国家参考中心，对囊性纤维化患者5年期间的真菌流行病学及多样性研究
Med Mycol. 2016 Nov 1;54(8):781-6. doi: 10.1093/mmy/myw035. Epub 2016 Jun 30.
8
Rapid and specific detection of section Fumigati and Aspergillus fumigatus in human samples using a new multiplex real-time PCR.使用新型多重实时聚合酶链反应快速、特异性检测人体样本中的烟曲霉组和烟曲霉
Diagn Microbiol Infect Dis. 2014 Oct;80(2):111-8. doi: 10.1016/j.diagmicrobio.2014.06.003. Epub 2014 Jun 19.
Zotero 插件